A Multicenter Study to Evaluate Safety and Tolerability in Patients With Chronic Heart Failure and Reduced Ejection Fraction From PARADIGM-HF Receiving Open Label LCZ696
A Multicenter Study to Evaluate Safety and Tolerability in Patients With Chronic Heart Failure and Reduced Ejection Fraction From PARADIGM-HF Receiving Open Label LCZ696
The purpose of this study was to collect safety and tolerability data on LCZ696 in eligible PARADIGM-HF patients who received open-label investigational drug. The parent PARADIGM-HF (NCT01035255) trial was terminated early due to compelling efficacy of LCZ696 in patients with heart failure with reduced ejection fraction (HFrEF) after the final pre-specified interim analysis in March 2014.
Inclusion Criteria:
Exclusion Criteria:
CABA, Buenos Aires C1221ADC, Argentina
Ciudad Autonoma de Bs As, Buenos Aires C1119ACN, Argentina
CABA, Buenos Aires F.D. C1179AAB, Argentina
St-Georges Beauce, Quebec G5Y 4T8, Canada
Liberec V Kristianova, Czech Republic 460 05, Czechia
Prague 10, Vrsovice, Czech Republic 10100, Czechia
Huy / OT Anderbeck, 38836, Germany
Muehlheim An Der Ruhr, 45468, Germany
Wetzlar-Naunheim, 35584, Germany
Hong Kong SAR, Hong Kong
Nyiregyháza, 4400, Hungary
N.Novgorod, 603005, Russia
Novosibirsk-117, 630117, Russia
S-Petersburg, 194354, Russia
Taladkwan, Changwat Nonthaburi 11000, Thailand
Muang, Thailand 12120, Thailand
Cheshire, CW1 4QJ, United Kingdom